Disclosed is the use of a dopamine receptor D2 inhibitor medicament for treating depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. The dopamine receptor D2 inhibitor medicament is formulated for administration in an administration cycle, the administration cycle comprising: i. administering the D2 receptor inhibitor to elevate amounts of the D2 receptors high affinity state, inducing dopamine receptor supersensitivity, ii. stopping administration of the D2 receptor inhibitor after dopamine receptor supersensitivity is induced, iii. restarting administration of the D2 receptor inhibitor after a time sufficient for D2 receptor supersensitivity to decrease and, optionally, repeating the stopping and restarting the administration cycle for a period of time effective to treat the depression, to improve cognition and/or to treat other syndromes, conditions or diseases for which anti-depressant agents are prescribed. The other syndromes, conditions or diseases for which anti-depressant agents are prescribed are selected from anxiety disorders, post-traumatic stress, phobias, sleep disorders, movement disorders, fibromyalgia and other pain syndromes, chronic fatigue syndrome, migraine, enuresis, overactive bladder, anorexia and/or bulimia, obsessive-compulsive disorder, hair pulling, nail biting and teeth grinding. Specific examples of D2 receptor inhibitors include antipsychotic agents such as haloperidol, chlorpromazine, fluphenazine, molindone, thiothixene, thioridazine, trifluoperazine, loxapine, perphenazine, prochlorperazine, pimozide, and zuclopenthixol and atypical antipsychotics selected from aripiprazole, clozapine, olanzapine, olanzapine/fluoxetine, quetiapine, risperidone and ziprasidone.
